Proteomic and phosphoproteomic analysis of rabies pathogenesis in the clinical canine brain and identification of a kinase inhibitor as a potential repurposed antiviral agent
Issued Date
2025-06-01
Resource Type
eISSN
19326203
Scopus ID
2-s2.0-105009152380
Journal Title
Plos One
Volume
20
Issue
6 June
Rights Holder(s)
SCOPUS
Bibliographic Citation
Plos One Vol.20 No.6 June (2025)
Suggested Citation
Chienwichai P., Ketsuwan K., Lumlertdacha B., Fa-Ngoen C., Supasawat P., Pulmanausahakul R., Masrinoul P., Thiangtrongjit T., Reamtong O. Proteomic and phosphoproteomic analysis of rabies pathogenesis in the clinical canine brain and identification of a kinase inhibitor as a potential repurposed antiviral agent. Plos One Vol.20 No.6 June (2025). doi:10.1371/journal.pone.0323931 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/111059
Title
Proteomic and phosphoproteomic analysis of rabies pathogenesis in the clinical canine brain and identification of a kinase inhibitor as a potential repurposed antiviral agent
Corresponding Author(s)
Other Contributor(s)
Abstract
Rabies is a fatal zoonosis caused by the rabies virus (RABV) that has afflicted humans for thousands of years. RABV infection leads to neurological symptoms and death; however, its pathogenesis in the brain is unclear, which complicates patient care. Given that no treatment exists for symptomatic cases, there is an urgent need for effective antiviral drugs. In this study, we aimed to investigate the pathogenic mechanism of RABV in the brain and screen for potential anti-RABV drugs. Protein samples were extracted from the brains of RABV-positive and RABV-negative dogs, and proteomic and phosphoproteomic analyses were conducted. The results showed that the synaptic vesicle cycle is critical to RABV pathogenesis. The kinases involved in the phosphorylation of proteins in the synaptic vesicle cycle were identified and examined as potential drug targets. Casein kinase 2 and protein kinase C were found to be key kinases for RABV replication, and five inhibitors of these enzymes were tested for their anti-RABV properties. Pretreating cells with the kinase inhibitor sunitinib significantly reduced the viral yield after RABV infection. Our findings suggest that RABV interferes with synaptic communication, which leads to rabies, and that inhibiting a vital kinase can reduce viral production. Hence, our findings have implications for the development of rabies treatment regimes.